Ct-053-ptsa Free Base Uses, Dosage, Side Effects and more
Ct-053-ptsa Free Base is under investigation in clinical trial NCT03758287 (Ct-053-ptsa Free Base (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative).
| Trade Name | Ct-053-ptsa Free Base |
| Generic | Ningetinib |
| Ningetinib Other Names | Ct-053 free base, Ct-053-ptsa free base, Ct053ptsa free base |
| Type | |
| Formula | C31H29FN4O5 |
| Weight | Average: 556.594 Monoisotopic: 556.212198213 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
